Celltrion Celebrates a Decade of Biosimilar Innovation in Europe
Celltrion Healthcare today launches a campaign to celebrate a decade of continuous biosimilar innovation in Europe. The campaign coincides with 10 years since the world’s first monoclonal antibody biosimilar infliximab, Remsima®, received regulatory approval from the European Medicines Agency (EMA).
Biosimilars have been pivotal in driving treatment advancements in immune-mediated inflammatory diseases (IMID) such as inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Thousands of patients in Europe and globally have benefitted from biosimilars since their initial approval, incurring both patient health and economic benefits.1
In the previous decade, there has been an ongoing pursuit to continue improving treatments and maximising patient quality of life. This sustained innovation and evolution of biosimilars has delivered benefits beyond their reference product. The development of new administration methods has ushered in a new era, offering patients a more convenient and accessible treatment options which can be administered at home.
Alongside the wide-ranging patient benefits, biosimilars have delivered savings to economies and healthcare systems across the world. Several analyses have found that use of biosimilars in place of their reference product in Europe could save hundreds of millions of Euros. For instance, the use of infliximab biosimilar had saved approximately £100 million in a year in the United Kingdom alone, according to the announcement made by United Kingdom’s National Health Service (NHS).2
Taehun Ha, Senior Vice President and Head of Europe Division at Celltrion Healthcare, said, “We are proud to recognise the tremendous impact that biosimilars have had on patients in Europe. Efforts to make high-quality biologics more affordable have paved the way for the widespread adoption of biosimilars across the continent and supported in improving patient outcomes. We at Celltrion remain committed to creating innovative treatments that prioritise the needs of patients and expand their treatment options.”
Professor Laurent Peyrin-Biroulet, Head of the Inflammatory Bowel Disease (IBD) group at the Gastroenterology Department of the University Hospital of Nancy, France, said, “Initially, we were intrigued by the arrival of biosimilars, especially with the first pivotal studies focusing solely on rheumatology. However, it became clear biosimilars offered a promising opportunity to reduce healthcare costs and improve the management of multiple diseases. Studies such as PLANETCD and NORSWITCH have added to the extensive evidence of their efficacy and safety, quickly reassuring us, in addition to our real-life experience. Biosimilars made it possible to reduce treatment prices - it was an economic revolution for patients and healthcare systems.”
In celebration of a decade of innovation and commitment to IMID treatment landscape, Celltrion is launching an innovative campaign across Europe. The campaign aims to highlight the positive impact of biosimilars to patients and healthcare systems, whilst reflecting on what the future could hold through continued innovation. Activities will include a global speaker tour, presentations by KOLs showcasing the latest clinical data, a report highlighting a decade of innovation and a celebration at United European Gastroenterology Week (UEGW) 2023 in Copenhagen.
Notes to Editors:
About the Campaign
This initiative aims to highlight the impact of infliximab biosimilars to patients and healthcare system in Europe over the last decade and spark discussion on the future of biosimilars and what can be achieved through harnessing the power of continued innovation. The campaign coincides with the 10th year since the approval of Remsima® in Europe.
A biosimilar is a biologic product developed and proven to be biologically identical to a previously approved biologic known as the reference product using the same active substances. Known for its high quality and affordability, the biosimilar has become an innovative medicine for patients with different diseases across the world including Europe.
Remsima® is the world's first biosimilar monoclonal antibody developed by Celltrion. Remsima® has continued expanding globally since its introduction in Europe in 2013 and has been authorised in over 100 countries worldwide as of January 2023, with a 55% market share in Europe in 2022.3
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 different countries.
Celltrion is committed to delivering affordable biologics and addressing healthcare needs, delivering innovations in treatments for patients with IMID, such as advances in treatment administration that enable people to access at-home treatment, allowing people to have an improved quality of life whilst managing their condition.
For more information, please visit: https://www.celltrionhealthcare.com
1 Jahnsen J., Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients. Therap Adv Gastroenterol. 2016 May;9(3):322-9. doi: 10.1177/1756283X16636764. Epub 2016 Mar 21. PMID: 27134662; PMCID: PMC4830106.
2 NHS (National Health Service). The NHS saves £324 million in a year by switching to better value medicines. Available at: https://www.england.nhs.uk/2018/07/nhs-saves-324-million-year-switching-to-better-value-medicines/
3 Celltrion, Inc. Fourth-Quarter and Full Year 2022 Earnings Release. https://www.celltrion.com/en-us/irs/resultdata
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
+44 (0) 7759 301620
+44 (0) 7423 534197
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Alignment Lab Achieves Major Milestone in Step Towards Agentic AI28.9.2023 08:00:00 EEST | Press release
Aligned AI, a leader in artificial intelligence (AI) research, has announced a groundbreaking AI advancement in misgeneralization, a critical challenge in the field of AI. It is the first to surpass a key benchmark called CoinRun by teaching an AI to “think” in human-like concepts. The technology underpinning the achievement opens the door to more precise, reliable, and controllable AI for a wide variety of real world applications. By teaching AI models to generalize in a manner more akin to agentic human cognition, Aligned AI’s innovation enables AI to correctly identify concepts across new situations and environments, reducing the need for prolonged production, testing, and retraining. Misgeneralization occurs when AI systems learn incorrect patterns and behaviors from their training data, and are not able to correctly adapt when presented with new information. This leads to unexpected, and often harmful, outcomes. Today’s foundation models suffer from varying degrees of misgeneraliz
Interactive Brokers Group Consolidates EU Operations into Ireland28.9.2023 07:00:00 EEST | Press release
Interactive Brokers Group (Nasdaq: IBKR), a leading global brokerage firm, today announced the consolidation of its European brokerage operations, with Interactive Brokers Central Europe (“IBCE”), based in Budapest Hungary, merging its client base and operations into the operations of Interactive Brokers Ireland (“IBIE”). The Group expects the merger of its European operations to produce measurable improvements in efficiency, while retaining its key talent pool and regional client focus. IB Ireland, based in Dublin and regulated by the Central Bank of Ireland, will manage the merged business, with IBCE continuing to provide its expertise to clients across the continent, and particularly in Central and Eastern Europe. Since commencing business following Brexit, these two operations have delivered and supported significant client growth as Interactive Brokers Group expands its presence across Europe. "This decision is consistent with the Group’s continuous focus on operational efficiency
TSMC Announces Breakthrough Set to Redefine the Future of 3D IC27.9.2023 22:17:00 EEST | Press release
TSMC (TSE: 2330, NYSE: TSM) today announced the new 3Dblox 2.0 open standard and major achievements of its Open Innovation Platform® (OIP) 3DFabric Alliance at the TSMC 2023 OIP Ecosystem Forum. The 3Dblox 2.0 features early 3D IC design capability that aims to significantly boost design efficiency, while the 3DFabric Alliance continues to drive memory, substrate, testing, manufacturing, and packaging integration. TSMC continues to push the envelope of 3D IC innovation, making its comprehensive 3D silicon stacking and advanced packaging technologies more accessible to every customer. “As the industry shifted toward embracing 3D IC and system-level innovation, the need for industry-wide collaboration has become even more essential than it was when we launched OIP 15 years ago,” said Dr. L.C. Lu, TSMC fellow and vice president of Design and Technology Platform. “As our sustained collaboration with OIP ecosystem partners continues to flourish, we’re enabling customers to harness TSMC’s le
Linksys Announces the Next Step in Home and Small Office Network Security27.9.2023 20:00:00 EEST | Press release
Linksys®, an iconic Home and Small Office connectivity company, announces in a statement of direction the new Cognitive™ Security capability, which will complement the newly released Designer Series through the end of the year. Cognitive Security technology will then be released in the soon-to-be announced Icon Series later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927310620/en/ Image of one white WiFi node, one grey WiFi node and one black WiFi node placed in a zig-zag formation (Photo: Business Wire) Designer Series products that will feature Cognitive Security are: Velop® Pro 6E – currently shipping Velop Pro 7 – shipping in September Velop Micro Router 6 – expected in October/November Velop Micro Mesh 6 – expected in October/November The term “Cognitive” in the technology space refers to “thinking technologies,” which can deterministically, either by user selection or automation, solve problems. In Pha
LumiThera Receives Notice of Award for National Eye Institute Grant to Support a 3rd Year Extension to LIGHTSITE III, the U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration27.9.2023 18:28:00 EEST | Press release
LumiThera Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI) of up to $2.3M in funding over two years. The NIH/NEI grant supports an open-label human clinical trial in U.S. intermediate dry age-related macular degeneration (dry AMD) subjects that participated in the pivotal LIGHTSITE III trial. LIGHTSITE IIIB will treat patients for 4 rounds of treatment over fourteen months. Sham patients in the previous study will be able to cross over and begin PBM treatment. The LIGHTSITE IIIB extension trial follows the successfully completed LIGHTSITE III trial, which showed a sustained, mean increase in best corrected vision acuity (BCVA) letter score of >5.0 letters from baseline at the 13- and 24-month timepoints (p < 0.0001) using the Co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom